Managers / Q3 2021 · view latest →
Pegasus Asset Management, Inc.
CIK 0001729049 · 44 WHIPPANY ROAD, SUITE 101, MORRISTOWN, NJ, 07960 · 8453699422
Summary
Pegasus Asset Management, Inc. reported $218M in U.S.-listed holdings across 76 positions for Q3 2021.
Its largest position, Schwab Strategic Tr, represents 8.7% of the portfolio.
Compared with Q2 2021, the fund opened 2 new positions and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 75.8% · $165M
- ETP · 15.9% · $35M
- Other · 6.1% · $13M
- REIT · 1.5% · $3M
- ADR · 0.7% · $2M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2021 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| ABNBAIRBNB INC | NEW | +12.7K | 12.7K | +$2M | $2M |
| SELECT SECTOR SPDR TR | NEW | +1.4K | 1.4K | +$202,000 | $202,000 |
| NVDANVIDIA CORPORATION | ADDED | +1.5K | 2.1K | +$15,000 | $427,000 |
| MARMARRIOTT INTL INC | TRIMMED | −10.3K | 8.6K | −$1M | $1M |
| DUKDUKE ENERGY CORP NEW | ADDED | +5.1K | 28.8K | +$466,000 | $3M |
| MPTMEDICAL PPTYS TRUST INC | ADDED | +18.6K | 139.6K | +$370,000 | $3M |
| INTCINTEL CORP | ADDED | +3.0K | 27.1K | +$91,000 | $1M |
| TDOCTELADOC HEALTH INC | ADDED | +1.1K | 10.3K | −$222,000 | $1M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2021
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $313M | 67 | Apr 21, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $325M | 68 | Feb 2, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $312M | 69 | Nov 3, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $292M | 72 | Jul 25, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $250M | 64 | Apr 21, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $265M | 66 | Feb 3, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $262M | 70 | Oct 21, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $261M | 71 | Jul 25, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $258M | 69 | May 2, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $233M | 69 | Feb 9, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $215M | 70 | Nov 2, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $225M | 72 | Aug 1, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $202M | 70 | Apr 24, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $185M | 72 | Jan 26, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $177M | 72 | Nov 8, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $184M | 72 | Aug 1, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $230M | 77 | Apr 20, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $244M | 76 | Jan 18, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $218M | 76 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $214M | 74 | Jul 29, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $197M | 73 | Apr 28, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $182M | 71 | Jan 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $160M | 71 | Oct 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $146M | 70 | Aug 11, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $121M | 67 | Apr 27, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $152M | 72 | Jan 22, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $137M | 69 | Oct 31, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $129M | 68 | Aug 5, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $121M | 66 | Apr 24, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $106M | 67 | Feb 12, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.